Evidence map›Paper›PMID 38699322›Full record

ArticlemedRxiv : the preprint server for health sciences2024

Emergence of SARS-CoV-2 Omicron Variant JN.1 in Tamil Nadu, India - Clinical Characteristics and Novel Mutations.

Sivaprakasam T Selvavinayagam, Sathish Sankar, Yean K Yong, Amudhan Murugesan, Suvaiyarasan Suvaithenamudhan, Kannan Hemashree, Manivannan Rajeshkumar, Anandhazhvar Kumaresan, Ramendra P Pandey, Saravanan Shanmugam and 13 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors.

Sivaprakasam T SelvavinayagamState Public Health Laboratory, Directorate of Public Health and Preventive Medicine, DMS Campus, Teynampet, Chennai 600 006, Tamil Nadu, India.
Sathish SankarDepartment of Microbiology, Centre for Infectious Diseases, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Chennai 600 077, Tamil Nadu, India.
Yean K YongLaboratory Center, Xiamen University Malaysia, 43900 Sepang, Selangor, Malaysia.
Amudhan MurugesanDepartment of Microbiology, Government Theni Medical College and Hospital, Theni-625 512, India.
Suvaiyarasan SuvaithenamudhanSchool of Biomedical Sciences, Sri Balaji Vidyapeeth, (Deemed to be University), Pondicherry 607 402, India.
Kannan HemashreeState Public Health Laboratory, Directorate of Public Health and Preventive Medicine, DMS Campus, Teynampet, Chennai 600 006, Tamil Nadu, India.
Manivannan RajeshkumarState Public Health Laboratory, Directorate of Public Health and Preventive Medicine, DMS Campus, Teynampet, Chennai 600 006, Tamil Nadu, India.
Anandhazhvar KumaresanState Public Health Laboratory, Directorate of Public Health and Preventive Medicine, DMS Campus, Teynampet, Chennai 600 006, Tamil Nadu, India.
Ramendra P PandeySchool of Health Sciences and Technology, UPES, Dehradun 248007, Uttarakhand, India.
Saravanan ShanmugamCenter for Infectious Diseases, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai 602105, Tamil Nadu, India.
Parthiban ArthydeviState Public Health Laboratory, Directorate of Public Health and Preventive Medicine, DMS Campus, Teynampet, Chennai 600 006, Tamil Nadu, India.
Masilamani S KumarState Public Health Laboratory, Directorate of Public Health and Preventive Medicine, DMS Campus, Teynampet, Chennai 600 006, Tamil Nadu, India.
Natarajan GopalanDepartment of Epidemiology and Public Health, Central University of Tamil Nadu, Thiruvarur 610 005, India.
Meganathan KannanBlood and Vascular Biology, Department of Biotechnology, Central University of Tamil Nadu, Thiruvarur 610 005, India.
Narayanaiah CheedarlaDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine, Division of Microbiology and Immunology, Emory National Primate Research Center, Emory Vaccine Center, Atlanta, GA, 30329, USA.
Hong Y TanSchool of Traditional Chinese Medicine, Xiamen University Malaysia, Sepang, Selangor, Malaysia.
Ying ZhangChemical Engineering, Xiamen University Malaysia, Sepang, Malaysia.
Marie LarssonDivision of Molecular Medicine and Virology, Department of Biomedical and Clinical Sciences, Linköping University, 58 183 Linköping, Sweden.ORCID 0000-0002-4524-0177
Pachamuthu BalakrishnanCenter for Infectious Diseases, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai 602105, Tamil Nadu, India.
Vijayakumar VeluDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine, Division of Microbiology and Immunology, Emory National Primate Research Center, Emory Vaccine Center, Atlanta, GA, 30329, USA.
Siddappa N ByrareddyDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68131, USA.
Esaki M ShankarInfection and Inflammation, Department of Biotechnology, Central University of Tamil Nadu, Thiruvarur 610 005, India.
Sivadoss RajuState Public Health Laboratory, Directorate of Public Health and Preventive Medicine, DMS Campus, Teynampet, Chennai 600 006, Tamil Nadu, India.

Funding

Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
Innate NKT Cells in HIV InfectionR37AI052731 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI NIXON, DOUGLAS F · 2007 to 2016
$3.1M
Innate NKT Cells in HIV InfectionR01AI052731 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI NIXON, DOUGLAS F · 2002 to 2006
$2.1M
NIAID NIH HHS R01 AI052731NIAID NIH HHS R37 AI052731NIH HHS P51 OD011132
6 · The paper itself

Abstract

In December 2023, we observed a notable shift in the COVID-19 landscape, when the JN.1 emerged as a predominant SARS-CoV-2 variant with a 95% incidence. We characterized the clinical profile, and genetic changes in JN.1, an emerging SARS-CoV-2 variant of interest. Whole genome sequencing was performed on SARS-CoV-2 positive samples, followed by sequence analysis. Mutations within the spike protein sequences were analyzed and compared with the previous lineages and sublineages of SARS-CoV-2, to identify the potential impact of these unique mutations on protein structure and possible functionality. Several unique and dynamic mutations were identified herein. Our data provides key insights into the emergence of newer variants of SARS-CoV-2 in our region and highlights the need for robust and sustained genomic surveillance of SARS-CoV-2.

Indexed as

JN.1 variantmutationOmicron variantSARS-CoV-2Spike proteinWhole genome sequencing

Identifiers

PMID38699322
PMCPMC11065016

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.